PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board

September 08, 2023 8:30 AM EDT | Source: PurMinds NeuroPharma

Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a Canadian neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders marred by neurodegeneration, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the Company's Scientific Advisory Board ("SAB").

Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience. He worked as a Professor for over 40 years at a number of prestigious universities in the field of medicinal chemistry, and is known for his research on 5-HT receptors, HDAC inhibitors, and GSK-3 inhibitors, and has over 100 patents and over 550 publications under his belt. Professor Kozikowski is also a serial pharmaceutical entrepreneur and one of the most prolific inventors in the psychedelic drug discovery and development field, having founded and co-founded multiple biotech companies such as Bright Minds Biosciences and StarWise Therapeutic LLC, with hundreds of NCEs designed under his stewardship. A number of his inventions are in various stages of clinical development or are now marketed drugs.

The extensive experience of Dr. Kozikowski in the application of chemistry to biological problems, especially his past success with novel therapeutics for brain diseases, will guide PurMinds to expand and accelerate its valuable clinical asset portfolio, especially non-hallucinogenic psychedelic-inspired NCEs for neurological disorders, such as Parkinson's and chemotherapy-induced cognitive impairment (CICI).

"We continue to expand the scientific and technological expertise of our SAB and the addition of Dr. Kozikowski is an incredibly exciting development for PurMinds. As an industry veteran with experience designing novel therapeutics for both psychiatric and neurological conditions, coupled with our robust drug development strategy of psychedelic-inspired combinatorial therapies, we will ensure that PurMinds will play a significant role in addressing devastating neurological disorders," said PurMinds' Chief Executive Officer, Janet Qi.

"Through my years of experience designing novel therapeutics for psychiatric and neurological conditions as well as cancer, I have been impressed with the potential of the Company's drug development pipeline aimed at promoting neuroplasticity and neuro-rejuvenation, while reducing neuroinflammatory processes, which are linked to neurological disorders," added Dr. Kozikowski.


PurMinds is a neuro-medicine development company pursuing breakthrough solutions to neurological disorders marred by neurodegeneration. PurMinds' clinical pipeline includes innovative therapeutics that combine proven Mode of Actions (MoA) with exciting new discoveries in Psychedelics and neuroplastogens and their ability to promote neuroplasticity and neuro-rejuvenation, with potentials for FDA "Breakthrough Designation", and fast track to Phase IIa. In addition, the company also operates a NeuroLabs in Ontario that was granted a Health Canada approved Controlled Substances license and can produce, formulate and supply pharma-grade Psychedelic compounds, including Psilocybin, MDMA, for global clinical trials and treatments.

PurMinds champions a de-risked business model including a multiple-target approach to drug development, as well as progressing short- and medium- term revenue path combined with long term value creation through development of novel therapeutics. For further information about PurMinds NeuroPharma, please visit the Company's website at purminds.com.

Media Contacts

Kristina Spionjack

HLTH Communications


Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to PurMinds' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions.

Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Some of the risks and other factors could cause results to differ materially from those expressed in the forward-looking statements which include, but are not limited to: the ability of PurMinds' to secure patent protection; the regulatory environment in which PurMinds operates; the ability of PurMinds to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; risks relating to general economic, market and business conditions; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/179968